C

Compass Therapeutics Inc.
NASDAQ:CMPX

Watchlist Manager
Compass Therapeutics Inc.
NASDAQ:CMPX
Watchlist
Price: 5.04 USD 1.61% Market Closed
Market Cap: 896.4m USD

Compass Therapeutics Inc.
Cash from Operating Activities

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Compass Therapeutics Inc.
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
C
Compass Therapeutics Inc.
NASDAQ:CMPX
Cash from Operating Activities
-$45.1m
CAGR 3-Years
-17%
CAGR 5-Years
-12%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Cash from Operating Activities
$20.9B
CAGR 3-Years
-3%
CAGR 5-Years
5%
CAGR 10-Years
15%
Gilead Sciences Inc
NASDAQ:GILD
Cash from Operating Activities
$9.7B
CAGR 3-Years
0%
CAGR 5-Years
2%
CAGR 10-Years
-6%
Amgen Inc
NASDAQ:AMGN
Cash from Operating Activities
$13.1B
CAGR 3-Years
10%
CAGR 5-Years
4%
CAGR 10-Years
3%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Cash from Operating Activities
$3.7B
CAGR 3-Years
-3%
CAGR 5-Years
3%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Cash from Operating Activities
$5.1B
CAGR 3-Years
-4%
CAGR 5-Years
18%
CAGR 10-Years
15%
No Stocks Found

Compass Therapeutics Inc.
Glance View

Market Cap
895m USD
Industry
Biotechnology

Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of proprietary antibody therapeutics. The company is headquartered in Boston, Massachusetts and currently employs 24 full-time employees. The company went IPO on 2020-11-13. Its pipeline of product candidates includes both angiogenesis-targeted agents and immune-oncology focused agents. These product candidates are designed for anti-tumor response to cancer. Its lead product candidate, CTX-471, is a monoclonal antibody agonist of CD137, a co-stimulatory receptor on immune cells. Its second product candidate, CTX-8371, is a bispecific antibody that simultaneously targets both PD-1 and PD-L1, the targets of checkpoint inhibitor antibodies. In addition to CTX-471 and CTX-8371, It is also developing a portfolio of bispecific and monoclonal antibody product candidates, which are in preclinical development. Its product candidate, CTX-009, is an anti-DLL4 x VEGF-A bispecific antibody, which has added to its pipeline through Trigr Therapeutics, Inc. (TRIGR).

CMPX Intrinsic Value
1.85 USD
Overvaluation 63%
Intrinsic Value
Price
C

See Also

What is Compass Therapeutics Inc.'s Cash from Operating Activities?
Cash from Operating Activities
-45.1m USD

Based on the financial report for Sep 30, 2025, Compass Therapeutics Inc.'s Cash from Operating Activities amounts to -45.1m USD.

What is Compass Therapeutics Inc.'s Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
-12%

Over the last year, the Cash from Operating Activities growth was 6%. The average annual Cash from Operating Activities growth rates for Compass Therapeutics Inc. have been -17% over the past three years , -12% over the past five years .

Back to Top